What Agesta Treats: Main Uses and Benefits

Agesta (Mifepristone) addresses therapeutic needs within two distinct medical domains, offering specific benefits to patients facing chronic metabolic dysfunction or requiring time-sensitive reproductive management. Its uses are relevant across domains involving heightened physiological activity.

---

Metabolic and Reproductive Clinical Contexts

Agesta is commonly used for managing severe, complex metabolic symptoms that arise from endogenous Cushing's syndrome, a condition characterized by high levels of cortisol, and for the medical management of early intrauterine pregnancy and confirmed early pregnancy loss (miscarriage). The medication supports efforts to manage persistent, elevated blood sugar in endocrine disorders and offers a non-surgical alternative for time-sensitive reproductive events.

“It provides supportive relief for two vastly different clinical situations: managing systemic metabolic imbalance and managing symptoms related to heightened physiological activity during early reproductive states.”

This supportive role may assist in maintaining functional stability for patients with chronic conditions and contributes to easing the overall symptom load during specific reproductive events.

---

Quick Fact: Support for Metabolic Symptoms Agesta contributes to easing the overall symptom load for patients with Cushing's syndrome associated with persistent hyperglycemia.

Regulatory References

1. Mifepristone tablet Prescribing Information from NIH DailyMed

Eligibility Map: Who Can and Cannot Use Agesta (Mifepristone) — Official Regulatory Information

The official population eligibility for Agesta is strictly defined by regulatory documents, establishing clear limitations based on clinical status, organ function, and life stage. The medicine is primarily approved for use in adult patients for its two distinct indications (early pregnancy management and hyperglycemia control in Cushing's syndrome).

Category	Regulatory Status	Description
Contraindicated Populations	Strictly Prohibited	Patients with chronic adrenal failure, inherited porphyrias, or known allergy to mifepristone or misoprostol. Also prohibited for those with confirmed or suspected ectopic pregnancy, hemorrhagic disorders, or if they are receiving concurrent long-term systemic corticosteroid therapy.
Condition-Specific Rules	Conditional/Restricted	Use is prohibited if an Intrauterine Device (IUD) is in place (must be removed). The medicine is not recommended for patients with severe hepatic or severe renal impairment due to limited study data, and may have dose limits for moderate impairment.
Age and Physiological Status	Adult Use Only	Safety and effectiveness have not been established in the general pediatric or geriatric populations. For non-reproductive use, the medicine is contraindicated in pregnant patients. Breastfeeding women should generally avoid use, especially during long-term therapy.

Agesta Interactions with other medicines and products

Official regulatory information describes several categories of substances that may alter the clinical effects or systemic exposure of this product. These interactions typically fall into pharmacokinetic and pharmacodynamic domains.

Category	Interacting Agents (Examples)	Interaction Profile
Enzyme Inducers	Medicines that induce certain liver enzymes, such as phenytoin, carbamazepine, or St. John's Wort.	These substances may cause a decrease in the plasma concentration of Agesta. This change in drug exposure may reduce the expected clinical effect.
Enzyme Inhibitors	Specific antiretroviral agents or potent inhibitors of certain cytochrome P450 enzymes.	The co-administration of these agents may lead to an increase in Agesta's systemic exposure, potentially modifying its effects.
Other Hormonal Agents	Estrogens or other progestins.	Concomitant use may result in additive hormonal effects or complex changes in plasma concentrations of both products. The clinical significance of these changes is noted in regulatory documents.

Drug interaction studies are conducted to characterize these effects, and the official label notes that certain medicinal product classes require careful consideration when used alongside Agesta. The profile explicitly requires awareness of co-administered agents that affect hepatic metabolic pathways to manage predictable alterations in exposure.

Agesta functions primarily as a highly specific inhibitor of the enzyme farnesyl pyrophosphate synthase (FPPS), which is critical in the mevalonate pathway. This enzyme catalyzes the condensation of geranyl pyrophosphate (GPP) with isopentenyl pyrophosphate (IPP) to form farnesyl pyrophosphate (FPP). By binding to and inactivating FPPS, Agesta disrupts the continuous production of FPP, which serves as a necessary precursor for the synthesis of isoprenoid lipids.

---

The suppression of FPP synthesis has a direct impact on the subsequent prenylation of small signaling proteins, notably the small GTPases such as Ras, Rho, and Rac. Prenylation—the attachment of a farnesyl or geranylgeranyl group—is required to anchor these proteins to the cell membrane, which is essential for their functional activation and involvement in intracellular signaling cascades. Specifically, Agesta's action prevents the necessary farnesylation of these proteins. This lack of prenylation keeps the GTPases sequestered in the cytosol, thus inhibiting their ability to relay proliferative, survival, and migratory signals within the cell. This molecular cascade leads to the system-level physiological consequence of modulating cellular adhesion and proliferation.

How to Use Agesta

Agesta (Mifepristone) is strictly intended for oral administration only. Its administration pattern is defined by the specific therapeutic context, requiring one of two highly divergent regimens.

---

Dosing for Approved Uses

Indication	Labeled Dosing Regimen	Frequency and Timing
Metabolic Symptoms	Starting dose is 300 mg, titratable in 300 mg increments up to a maximum of 1200 mg.	Once daily, must be taken with a meal.
Reproductive Management	A single dose of 200 mg.	Single-day administration, followed by co-administration of misoprostol 24 to 48 hours later.

---

Administration Requirements and Adjustments

Regardless of the regimen, the tablet must be swallowed whole and should not be split, crushed, or chewed.

The ongoing regimen for metabolic symptoms is subject to specific dose adjustments based on organ function. The maximum dose must be limited to 600 mg once daily for patients with renal impairment or mild-to-moderate hepatic impairment. Furthermore, if the long-term regimen is interrupted for more than 14 days, the dose must be reinitiated at the lowest 300 mg dose.

For reproductive management, the prescribing and dispensing of mifepristone is subject to a specialized oversight program, which mandates specific procedural steps and a mandatory follow-up assessment.

Research evidence / Overview of studies for Agesta (Mifepristone)

This section provides a summary of the official research studies and clinical trials that have evaluated Agesta, focusing on the available evidence structure and what remains to be fully understood, according to scientific and regulatory sources. This information is derived from studies and does not constitute medical advice or treatment recommendations.

---

Evidence for use in Endogenous Cushing's Syndrome

The evidence for Agesta in patients with Cushing's syndrome—a condition marked by systemic or functional imbalance due to high cortisol levels—was studied for its potential role in managing associated symptoms. The primary research examined adult patients whose condition was refractory or inoperable, often including those with other complex conditions like Type 2 Diabetes Mellitus or hypertension.

The research included open-label, prospective Phase III clinical trials. These studies examined outcomes related to systemic or functional imbalance, such as blood glucose levels (e.g., HbA1c) and blood pressure measurements, over a defined time interval, typically around six months. Studies report how symptoms evolved in the observed populations, describing patterns in glucose and blood pressure biomarkers that were observed in some studies. Due to the rarity of the condition, sample sizes were modest, and the non-blinded nature of the key efficacy data means evidence is limited when considering subjective patient-reported outcomes.

---

Evidence for use in Early Intrauterine Pregnancy Management and Early Pregnancy Loss

The research exploring the use of a regimen including Agesta for early intrauterine pregnancy management and confirmed early pregnancy loss (miscarriage) was evaluated in a large body of data. This evidence base consists of numerous Randomized Controlled Trials (RCTs) and systematic reviews.

Studies Evaluating Regimen Components and Resolution Endpoints

The key outcomes studies explored were the rate of complete resolution—meaning the full expulsion of the tissue without requiring subsequent surgery—and the time needed to reach that endpoint. The research provides insight into short-term changes that data show patterns related to resolution. Studies report how symptoms evolved in the observed populations, comparing resolution rates between the pretreatment regimen and those that did not include it.

Research Gaps and Remaining Uncertainties

There is limited information for long-term outcomes regarding the durability of the observed metabolic changes in Cushing's patients or the long-term impact on future reproductive health. Additionally, for the reproductive indication, the research describes studies focusing on the combination regimen, and comparative evidence for Agesta's isolated effect is limited. Overall, research is ongoing, and existing studies provide limited insight into how individual responses may differ from the group patterns reported in the trials.

Key Studies & References Mifepristone tablet Prescribing Information from NIH DailyMed

Common questions about Agesta (FAQ)

---

Q: If I'm taking Agesta long-term for Cushing's syndrome, how often do I need follow-up blood tests?

Official regulatory information specifies the need for regular monitoring for patients on long-term Agesta therapy. This typically includes checking liver function tests (LFTs) and assessing the heart's electrical activity using an ECG to monitor for potential side effects. The frequency of these tests and the monitoring of specific biomarkers are determined by the prescribing healthcare provider.

---

Q: What should I do if Agesta causes stomach upset or nausea?

According to official product information, nausea and vomiting are classified as Very Common side effects, meaning they are frequently reported. Regulatory labels note that if these side effects become severe or concerning, patients are advised to contact a healthcare professional for guidance.

---

Q: How soon after stopping Agesta will it be completely out of my system?

Pharmacokinetic data indicates the active ingredient in Agesta has a long mean terminal half-life of approximately 85 hours. Due to the risk of adrenal insufficiency, official information states that patients who stop long-term therapy must be monitored by a healthcare professional for at least four weeks after the last dose.

---

Q: How does Agesta actually work in the body at a cellular level?

The official information describes Agesta's mechanism as working through two primary pathways: acting as an Antiprogestin and as a Glucocorticoid Receptor Antagonist. In simple terms, it works by blocking the activity of certain hormones, such as progesterone and cortisol, by binding to their receptors. This action interrupts hormone-driven biological processes, which is central to its therapeutic effects.

---

Q: Can Agesta be used to treat early pregnancy loss (miscarriage)?

Studies and official information indicate that the active ingredient in Agesta is used for the medical termination of intrauterine pregnancy. Official information indicates the drug's active ingredient is also used as part of regimens intended for the management of early pregnancy loss.

---

Q: What is the maximum daily dose of Agesta I can take?

Regulatory documents cite a maximum daily dose for metabolic symptoms, but this dose is often conditional. Official information states that the dose must be limited for patients with certain conditions, such as existing renal or mild-to-moderate hepatic impairment (kidney or liver problems). A healthcare provider determines the appropriate daily dose.

---

Q: Is Agesta safe to take with common herbal supplements like St. John's Wort?

Official regulatory labeling explicitly identifies St. John's Wort as a strong CYP3A inducer. This means that co-administering this supplement is associated with an increased rate at which the liver processes Agesta. This interaction may decrease the concentration of Agesta in the body, which could potentially reduce its expected clinical effect.

Official Storage and Disposal Requirements

Agesta (Mifepristone) tablets must be stored according to specific conditions detailed in regulatory documents to ensure product stability.

Storage Component	Required Condition
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection	Protect from light; keep in the original container
Child Safety	Store out of the reach and sight of children

The medicine should not be removed from its original container until the time of administration. Disposal of any unused or expired product must follow local requirements and must not involve disposal via household waste or by pouring into wastewater, as directed by official regulatory guidelines.